Abstract
Autologous hematopoietic stem cell transplantation can improve the remission rate and survival rate of patients with multiple myeloma who were treated with large doses of chemotherapy, and for low-risk patients, viable autologous hematopoietic stem cell transplantation has gradually replaced the traditional chemotherapy and became the standard first-line treatment for newly diagnosed multiple myeloma patients under the age of 65. Autologous hematopoietic stem cell transplantation in patients with multiple myeloma is the key to the success of treatment. Key words: Nursing care; Multiple myeloma; Autologous stem cell transplantation
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
